LINC02334: A Long Intergenic Non-Protein Coding RNA and Potential Drug Target

Target Name: LINC02334

NCBI ID: G101929077

LINC02334

Other Name(s): Long intergenic non-protein coding RNA 2334, transcript variant X1 | LINC02334 variant X1 | long intergenic non-protein coding RNA 2334

LINC02334: A Long Intergenic Non-Protein Coding RNA and Potential Drug Target

LINC02334 is a long non-coding RNA (lncRNA) with a length of approximately 2200 nucleotides. It is found in various tissues and cell types of the human body. LINC02334 is not a protein, which means it does not have any amino acid sequences. Despite its non-protein nature, LINC02334 has been shown to play a critical role in various cellular processes.

One of the key features of LINC02334 is its location in the intergenic region. Intergenic region is a region that lies between the exons of two different genes. It is a region that is involved in the regulation of gene expression and has been associated with various diseases, including cancer.

LINC02334 is a non-protein coding RNA (ncRNA), which means it does not have any amino acid sequences. However, it has been shown to have RNA binding proteins (RBP) that interact with specific DNA sequences. These RBP interactions are important for the regulation of gene expression and are a potential drug target for LINC02334.

Diseases associated with LINC02334

LINC02334 has been associated with various diseases, including cancer. One of the most well-studied associations is with cancer. LINC02334 has been shown to be highly expressed in various types of cancer, including breast, ovarian, and prostate cancers.

In addition to its association with cancer, LINC02334 has also been associated with various other diseases. For example, it has been shown to be highly expressed in neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. It has also been associated with various cardiovascular diseases, such as heart failure and hypertension.

Potential drug targets

The potential drug targets for LINC02334 are numerous. One of the most promising targets is its interaction with RBP. LINC02334 has been shown to have RBP interactions that are involved in the regulation of gene expression. These interactions may be useful for the development of drugs that target the regulation of gene expression by RBP.

Another potential drug target for LINC02334 is its association with cancer. LINC02334 has been shown to be highly expressed in various types of cancer, including breast, ovarian, and prostate cancers. Targeting LINC02334 with drugs that inhibit its expression or activity may be a promising strategy for the treatment of these cancers.

Another potential drug target for LINC02334 is its association with neurodegenerative diseases. LINC02334 has been shown to be highly expressed in neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Targeting LINC02334 with drugs that inhibit its expression or activity may be a promising strategy for the treatment of these diseases.

Conclusion

In conclusion, LINC02334 is a long non-coding RNA that has been associated with various diseases, including cancer. Its interaction with RBP and its association with cancer and neurodegenerative diseases make it a promising drug target. Further research is needed to fully understand the role of LINC02334 in disease and to develop effective drugs that target its activity.

Protein Name: Long Intergenic Non-protein Coding RNA 2334

The "LINC02334 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02334 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets